Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 13/20 | 0.58 |
| ▸ | CA2 | P00918 | 8/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.58 |
| ▸ | CA1 | P00915 | 9/20 | 0.51 |
| ▸ | CA7 | P43166 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17233254 | 0.90 | CA12 (0.61) | CA12CA2CA14CA1CA7 | |
| SCHEMBL23762491 | 0.85 | CA12 (0.59) | CA12CA2CA14CA1CA7 | |
| SCHEMBL22404329 | 0.85 | CA12 (0.59) | CA12CA2CA14CA1CA7 | |
| SCHEMBL23762313 | 0.84 | TDP1 (0.58) | CA12CA2CA14CA1CA7 | |
| SCHEMBL23762328 | 0.83 | TDP1 (0.61) | CA12CA2CA14CA1CA7 | |
| SCHEMBL22404312 | 0.83 | CA12 (0.60) | CA12CA2CA14CA1CA7 | |
| SCHEMBL20646495 | 0.81 | CA12 (0.63) | CA12CA2CA14CA1CA7 | |
| SCHEMBL1145926 | 0.81 | CA12 (0.63) | CA12CA2CA14CA1CA7 | |
| SCHEMBL19636495 | 0.81 | CA12 (0.55) | CA12CA2CA14CA1CA7 | |
| SCHEMBL22398423 | 0.80 | CA12 (0.57) | CA12CA2CA14CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740723-B1 | SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2017-05-10 | — | — | EP | disclosed |
| US-9073906-B2 | Sulfamide derivative having an adamantyl group and its pharmaceutically acceptable salt | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-07-07 | — | — | US | disclosed |
| EP-2740723-A2 | SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Korea Research Institute of Chemical Technology (KR) | 2014-06-11 | — | — | EP | disclosed |
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-01-23 | — | — | US | disclosed |
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | HSD11B1, HSD11B2, HSD3B1 | CA12 838/4885CA2 1279/4885CA14 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.